In spite of the extraordinary efforts and the significant financial investment behind every drug candidate, only a small fraction will ever make it through clinical trials – less than 10%.
CatSci partners with three leading UK organisations to offer expert support across the pharmaceutical supply chain
Cardiff, UK – CatSci Ltd, a scientifically led, commercially minded and award-winning innovation partner, today announced partnerships with three UK companies across the pharmaceutical supply chain – M2M Pharmaceuticals (M2M Pharma), New Path Molecular (NPM) and Upperton Pharma Solutions (Upperton).
Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule
Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company will, in the fourth quarter of 2020, start the first ever human trial of a drug candidate nanoformed using Nanoform’s proprietary CESS® technology.
The inaugural MedTech Integrates conference launched as a fully virtual event last Thursday, inspired by the ongoing success of the Pharma and Bio Integrates events.
Medical devices designed to enhance patients’ lives can be susceptible to microbial infection resulting in problems including local and systemic infection, implant replacement, patient pain and discomfort and associated healthcare costs. Perfectus Biomed Group support your R&D helping you to identify, simulate and control microbial infection.
If we are to beat cancer, early detection and diagnosis (ED&D) are arguably the most effective means we have at our disposal. Patients diagnosed early have the best chance of curative treatment and long-term survival. Despite this, we are currently only diagnosing just over half of patients at an early stage, demonstrating significant opportunity for improvement.